Hartmann et al. further identified that CXCR4-driven adhesion enhances chemotherapy resistance in SCLC by activating integrin signaling, suggesting that CXCR4 inhibition could prevent tumor-stroma interactions that contribute to residual disease and relapses (Hartmann et al., 2005). The gene discussed is CXCR4; the disease is neoplasm.